“Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Metastatic Cutaneous Squamous Cell Carcinoma”. 2018. SKIN The Journal of Cutaneous Medicine 2 (December): S79. https://doi.org/10.25251/skin.2.supp.79.